Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.60    0.40 (0.26%)
Bid:
156.60
Ask:
157.00
Spread: 0.40 (0.255%)
Market Cap: £895.40m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading update

14 Jan 2021 07:00

RNS Number : 6200L
Elementis PLC
14 January 2021
 

Elementis plc

Trading Update

Sequential revenue improvement, FY 20 adjusted operating profit $81-83m

Significant reduction in net debt, anticipated to be under $415m

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months ended 31 December 2020.

Fourth quarter business performance

 

Fourth quarter revenue is expected to be ahead of the third quarter driven by improved volumes and largely stable pricing. Overall performance in the quarter is anticipated to be in line with management expectations, helped by tight cost management and supply chain efficiencies. As a result, adjusted operating profit for 2020 is expected to be $81-83m.

· Coatings has continued to perform well in Q4, albeit at lower levels than the prior year period, and remains on track to deliver improved operating margins versus the prior year.

 

· Personal Care sales remain materially lower than the prior year period in both Cosmetics and AP Actives, due to the continuation of COVID-19 related social and travel restrictions that have reduced consumption. Q4 performance is anticipated to be in line with Q3 levels. 

 

· Talc volumes continued to recover, driven by improved long-life plastic demand for automotive applications and resilience in coatings. As a result, Q4 revenue is expected to be ahead of the prior year period.

· Chromium demand has sequentially improved, driven by increased demand for industrial applications such as leather tanning and metal plating. As a result, Q4 revenue is anticipated to be broadly in line with the prior year period.

 

· Energy continues to experience very weak market conditions with rig counts and activity levels remaining subdued.

 

In the fourth quarter we have continued to deliver against our Innovation, Growth and Efficiency strategy. For full year 2020 we launched 12 new products, captured over $30m of new business and delivered $15m of in year cost savings.

For 2021, whilst our new business and innovation pipelines are encouraging, we continue to face temporary demand challenges from COVID-19, particularly in Personal Care where we expect performance will recover when social and travel restrictions are lifted. As a result of the recently announced closure of our plant in Charleston, West Virginia, we have made further progress underpinning $10m of supply chain cost efficiencies, and our new AP Actives plant in India remains on track for mid-2021 start up.

Liquidity and balance sheet

 

As result of tight working capital management and disciplined capital expenditure, net debt* at the end of 2020 is anticipated to be under $415m, representing a significant reduction from $454m at the start of the year.

 

Elementis has a proven cash generative business model, with average operating cash conversion above 90% over the last 3 years, and the Group continues to operate with ample liquidity, with over $300m immediately available through committed lending facilities.

 

 

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson Tel: 020 7353 4200

David Allchurch

 

* Excluding IFRS 16 impact

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFZGMMRFGGMZM
Date   Source Headline
1st Sep 20229:00 amRNSTotal Voting Rights
2nd Aug 20227:00 amRNSHalf-year Report
1st Aug 202211:08 amRNSTotal Voting Rights
21st Jul 20223:14 pmRNSHolding(s) in Company
1st Jul 20229:47 amRNSTotal Voting Rights
20th Jun 20221:54 pmRNSHolding(s) in Company
17th Jun 20224:35 pmRNSPrice Monitoring Extension
3rd May 202210:27 amRNSTotal Voting Rights
3rd May 20227:00 amRNSCompany Secretary Change
26th Apr 202212:28 pmRNSResult of AGM
26th Apr 20227:00 amRNSAGM Trading Statement
5th Apr 20224:17 pmRNSDirector/PDMR Shareholding
23rd Mar 20223:52 pmRNSAdditional Listing
22nd Mar 20224:18 pmRNSAnnual Financial Report & Notice of AGM
15th Mar 20227:53 amRNSDirectorate Change
8th Mar 202212:18 pmRNSDirector/PDMR Shareholding
8th Mar 202212:17 pmRNSDirector/PDMR Shareholding
8th Mar 202211:47 amRNSHolding(s) in Company
8th Mar 202210:43 amRNSDirector/PDMR Shareholding
8th Mar 202210:39 amRNSDirector/PDMR Shareholding
7th Mar 20223:26 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSPreliminary results year ended 31 December 2021
1st Mar 20222:03 pmRNSDirector Declaration
1st Mar 202211:18 amRNSBlock listing Interim Review
18th Jan 20227:00 amRNSTrading Update
10th Jan 20221:20 pmRNSHolding(s) in Company
4th Jan 202211:48 amRNSTotal Voting Rights
1st Dec 202111:10 amRNSTotal Voting Rights
10th Nov 202112:20 pmRNSHolding(s) in Company
3rd Nov 202111:25 amRNSHolding(s) in Company
1st Nov 20211:44 pmRNSTotal Voting Rights
28th Oct 20217:00 amRNSQ3 Trading Update
19th Oct 20216:10 pmRNSDirector Declaration
5th Oct 20218:42 amRNSDirector Declaration
1st Sep 20219:49 amRNSBlock listing Interim Review
2nd Aug 202110:22 amRNSTotal Voting Rights
29th Jul 20217:00 amRNSDirectorate Change
29th Jul 20217:00 amRNSHalf-year Report
5th Jul 202110:15 amRNSTotal Voting Rights
25th Jun 20212:59 pmRNSHolding(s) in Company
23rd Jun 20212:56 pmRNSDirector Declaration
1st Jun 202110:06 amRNSTotal Voting Rights
13th May 20213:39 pmRNSResult of AGM
13th May 20217:00 amRNSAGM Trading Statement
22nd Apr 20213:26 pmRNSAdditional Listing
20th Apr 20214:18 pmRNSResponse to Innospec Inc. announcement
20th Apr 20212:36 pmRNSPress Speculation Re Possible Offer for Elementis
9th Apr 20215:15 pmRNSAnnual Financial Report
7th Apr 20215:31 pmRNSDirector/PDMR Shareholding
1st Apr 20218:49 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.